Neuroprotection by selegiline and other MAO inhibitors.
A proposal for the nomination of the father of monoamine oxidase inhibitors is presented. A brief history of the human clinical pharmacology of selegiline is considered including the results of two major prospective ongoing clinical trials and recent evidence on the effects of sustained selegiline therapy on postural blood pressures in parkinsonians is discussed.
Stern
G
G
Department of Clinical Neurology, University College, London Hospitals, United Kingdom.
D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D018696:Neuroprotective Agents / Q000494:pharmacology*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D011187:Posture; D011446:Prospective Studies; D012642:Selegiline / Q000494:pharmacology* / Q000627:therapeutic use
D000978:Antiparkinson Agents; D008996:Monoamine Oxidase Inhibitors; D018696:Neuroprotective Agents; D012642:Selegiline